On May 31, 2025, Viatris Inc. (NASDAQ:VTRS) became the subject of a securities fraud class action lawsuit filed in the U.S. District Court for the Western District of Pennsylvania. The suit alleges that between August 8, 2024, and February 26, 2025, the company and certain executives made materially false or misleading statements regarding the operational status of its Indore, India manufacturing facility.
Ralf Kleemann/Shutterstock.com
The complaint centers on Viatris' public assurances that its facilities were in "good operating condition" and committed to "the highest quality manufacturing standards." However, following a failed inspection, the U.S. Food and Drug Administration issued a Warning Letter and Import Alert in December 2024 that affected 11 products, including the cancer drug Lenalidomide.
On February 27, 2025, Viatris (NASDAQ:VTRS) disclosed that the inspection issues would negatively impact 2025 revenue by roughly $500 million and earnings from operations by about $385 million. This revelation led to a 15% drop in Viatris' stock price, from $11.24 to $9.53 per share.
Investors who purchased Viatris securities during the specified period have until June 3, 2025, to seek appointment as lead plaintiff in the lawsuit.
While we acknowledge the potential of VTRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None.